DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Chapple CR, Kaplan SA, Mitcheson D. et al.
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder.
Eur Urol 2013;
63: 296-305
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.